Malignancy, lung involvement, and cardiovascular diseases are the main causes of mortality in IIM.(53) The presence and the type of myositis‐specific antibodies are crucial for identifying patients likely to develop a rapidly progressive interstitial lung disease (e.g., anti‐MDA5) or a malignancy (e.g., Anti‐TIF1‐γ), but do not permit to predict with certainty such complications. Here, IFIH1 is linked to myositis disease.